{"id":723,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"},"modified":"2026-10-11T08:32:04","modified_gmt":"2026-10-11T08:32:04","slug":"%d8%aa%d9%8a%d8%b1%d8%b2%d9%8a%d8%a8%d8%a7%d8%aa%d9%8a%d8%af-%d9%81%d9%8a-%d8%af%d8%b1%d8%a7%d8%b3%d8%a9-%d8%b4%d9%85%d9%84%d8%aa-12539-%d8%a8%d8%a7%d9%84%d8%ba%d9%8b%d8%a7-%d8%b9%d9%84%d9%89-%d9%85","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/ar\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","title":{"rendered":"\u062a\u064a\u0631\u0632\u064a\u0628\u0627\u062a\u064a\u062f SURMOUNT-1: \u0642\u0631\u0627\u0621\u0629 \u0623\u0631\u0642\u0627\u0645 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0648\u0632\u0646"},"content":{"rendered":"

Start with the question<\/h2>\n

SURMOUNT-1 tested whether tirzepatide changed body weight in adults with obesity or overweight and a related complication. Diabetes was excluded. This matters because a result from one population does not automatically describe another. Tirzepatide targets GIP and GLP-1 receptors; the trial tested outcomes rather than relying on that mechanism alone.<\/p>\n

Why include a placebo group?<\/h2>\n

The 2,539 participants were randomly assigned to three tirzepatide groups or placebo and followed for 72 weeks. Random assignment helps make groups comparable. A placebo group also shows what happens in the study setting without the active compound. Simply comparing a person with their own starting weight cannot provide the same information. [1]<\/p>\n

\n
    \n
  1. 01<\/b>Tirzepatide groups<\/span><\/li>\n
  2. 02<\/b>Placebo group<\/span><\/li>\n
  3. 03<\/b>Compare at week 72<\/span><\/li>\n<\/ol>
    Reading guide: separates the study questions; not raw data or a prediction of product performance.<\/figcaption><\/figure>\n

    What were the reported changes?<\/h2>\n

    Average weight changes were \u221215.0%, \u221219.5% and \u221220.9% in the 5, 10 and 15 mg groups, versus \u22123.1% with placebo. The percentages describe change from starting weight. Trial group labels are reported here only to explain the paper, not to recommend a regimen. [1]<\/p>\n

    How big is the difference?<\/h2>\n

    Subtracting the two percentages gives 17.8 percentage points. This is a difference between group averages. For a hypothetical 100 kg starting weight, a 20.9% reduction would mean 20.9 kg. The example explains the unit; actual participants had different starting weights and outcomes. An average also cannot show who stopped treatment or had adverse events.<\/p>\n

    Do not skip tolerability<\/h2>\n

    Digestive events were common. Discontinuation because of adverse events was 4.3%, 7.1% and 6.2% in the three tirzepatide groups, compared with 2.6% for placebo. The study does not directly rank tirzepatide against retatrutide. Differences between separate trials can reflect their populations, timing and analysis. [1]<\/p>\n

    Find the related product<\/h2>\n

    The product page identifies NHD\u2019s tirzepatide research material and inquiry options. It is not the finished clinical product used in SURMOUNT-1. Tell the team the laboratory question, required variant, quantity and records needed so that the material request can be checked separately from the publication.<\/p>\n

    \n

    Related research products<\/h2>\n
    \n
    \n

    Tirzepatide<\/h3>\n

    Material for GIP\/GLP-1 receptor research.<\/p>\n

    View product and variants \u2192<\/a><\/article>\n<\/div>\n

    For a material inquiry, specify the name, quantity, laboratory purpose and records needed. The team will confirm the available scope.<\/p>\n

    Discuss material requirements \u2192<\/a><\/section>\n

    \n

    Original research and reading notes<\/h2>\n
      \n
    1. SURMOUNT-1 \u00b7 NEJM 2022<\/a><\/li>\n<\/ol>\n

      Study amounts and preparations identify experimental conditions, not recommended use. AI-assisted research explanation; sources checked 11 October 2026. NHD catalog materials are for research, development and manufacturing, not human or veterinary use.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

      \u0645\u0627 \u062a\u062e\u0628\u0631\u0646\u0627 \u0628\u0647 2,539 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u0648\u0646\u060c \u0648\u062b\u0644\u0627\u062b \u0645\u062c\u0645\u0648\u0639\u0627\u062a \u062f\u0631\u0627\u0633\u064a\u0629 \u0648\u0645\u0642\u0627\u0631\u0646\u0629 \u0628\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0648\u0647\u0645\u064a.<\/p>","protected":false},"author":0,"featured_media":4035,"template":"","class_list":["post-723","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nTirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers | NHD<\/title>\n<meta name=\"description\" content=\"What 2,539 participants, three study groups and a placebo comparison tell us.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/ar\/\u062f\u0631\u0627\u0633\u0627\u062a-\u0627\u0644\u062d\u0627\u0644\u0629\/\u062a\u064a\u0631\u0632\u064a\u0628\u0627\u062a\u064a\u062f-\u0641\u064a-\u062f\u0631\u0627\u0633\u0629-\u0634\u0645\u0644\u062a-12539-\u0628\u0627\u0644\u063a\u064b\u0627-\u0639\u0644\u0649-\u0645\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers\" \/>\n<meta property=\"og:description\" content=\"What 2,539 participants, three study groups and a placebo comparison tell us.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/ar\/\u062f\u0631\u0627\u0633\u0627\u062a-\u0627\u0644\u062d\u0627\u0644\u0629\/\u062a\u064a\u0631\u0632\u064a\u0628\u0627\u062a\u064a\u062f-\u0641\u064a-\u062f\u0631\u0627\u0633\u0629-\u0634\u0645\u0644\u062a-12539-\u0628\u0627\u0644\u063a\u064b\u0627-\u0639\u0644\u0649-\u0645\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-11T08:32:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-723.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u062f\u0642\u064a\u0642\u062a\u0627\u0646\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"name\":\"Tirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers | NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-723.jpg\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-10-11T08:32:04+00:00\",\"description\":\"What 2,539 participants, three study groups and a placebo comparison tell us.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-723.jpg\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-723.jpg\",\"width\":1200,\"height\":800,\"caption\":\"Editorial comic illustration: Inside SURMOUNT-1. Conceptual cover, not experimental imagery.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/etudes-de-cas\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u062a\u064a\u0631\u0632\u064a\u0628\u0627\u062a\u064a\u062f SURMOUNT-1: \u0642\u0631\u0627\u0621\u0629 \u0623\u0631\u0642\u0627\u0645 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0648\u0632\u0646 | NHD","description":"\u0645\u0627 \u062a\u062e\u0628\u0631\u0646\u0627 \u0628\u0647 2,539 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u0648\u0646\u060c \u0648\u062b\u0644\u0627\u062b \u0645\u062c\u0645\u0648\u0639\u0627\u062a \u062f\u0631\u0627\u0633\u064a\u0629 \u0648\u0645\u0642\u0627\u0631\u0646\u0629 \u0628\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0648\u0647\u0645\u064a.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/ar\/\u062f\u0631\u0627\u0633\u0627\u062a-\u0627\u0644\u062d\u0627\u0644\u0629\/\u062a\u064a\u0631\u0632\u064a\u0628\u0627\u062a\u064a\u062f-\u0641\u064a-\u062f\u0631\u0627\u0633\u0629-\u0634\u0645\u0644\u062a-12539-\u0628\u0627\u0644\u063a\u064b\u0627-\u0639\u0644\u0649-\u0645\/","og_locale":"ar_AR","og_type":"article","og_title":"Tirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers","og_description":"What 2,539 participants, three study groups and a placebo comparison tell us.","og_url":"https:\/\/nhdbio.com\/ar\/\u062f\u0631\u0627\u0633\u0627\u062a-\u0627\u0644\u062d\u0627\u0644\u0629\/\u062a\u064a\u0631\u0632\u064a\u0628\u0627\u062a\u064a\u062f-\u0641\u064a-\u062f\u0631\u0627\u0633\u0629-\u0634\u0645\u0644\u062a-12539-\u0628\u0627\u0644\u063a\u064b\u0627-\u0639\u0644\u0649-\u0645\/","og_site_name":"NHD","article_modified_time":"2026-10-11T08:32:04+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-723.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u062a\u0627\u0646"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","name":"\u062a\u064a\u0631\u0632\u064a\u0628\u0627\u062a\u064a\u062f SURMOUNT-1: \u0642\u0631\u0627\u0621\u0629 \u0623\u0631\u0642\u0627\u0645 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0648\u0632\u0646 | NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-723.jpg","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-10-11T08:32:04+00:00","description":"\u0645\u0627 \u062a\u062e\u0628\u0631\u0646\u0627 \u0628\u0647 2,539 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u0648\u0646\u060c \u0648\u062b\u0644\u0627\u062b \u0645\u062c\u0645\u0648\u0639\u0627\u062a \u062f\u0631\u0627\u0633\u064a\u0629 \u0648\u0645\u0642\u0627\u0631\u0646\u0629 \u0628\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0648\u0647\u0645\u064a.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-723.jpg","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-723.jpg","width":1200,"height":800,"caption":"Editorial comic illustration: Inside SURMOUNT-1. Conceptual cover, not experimental imagery."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/fr\/etudes-de-cas\/"},{"@type":"ListItem","position":3,"name":"Tirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u0645\u0648\u0627\u062f \u062e\u0627\u0645 \u0628\u0628\u062a\u064a\u062f\u064a\u0629 \u0648\u062a\u062e\u0644\u064a\u0642 \u0627\u0644\u0628\u0628\u062a\u064a\u062f\u0627\u062a \u062d\u0633\u0628 \u0627\u0644\u0637\u0644\u0628","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/case_study\/723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/case_study\/723\/revisions"}],"predecessor-version":[{"id":4184,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/case_study\/723\/revisions\/4184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media\/4035"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media?parent=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}